View Post

Quantum Leap Healthcare Collaborative™ announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study

In Clinical Studies News by Barbara Jacoby

Source: PR Newswire From: yahoo.com Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. This study arm, known as the I-SPY-2 Endocrine Optimization Pilot Protocol (EOP), is focused on patients …